oa SA Pharmaceutical Journal - Vortioxetine : more than just another selective serotonin reuptake inhibitor : drug info - new product focus
|Article Title||Vortioxetine : more than just another selective serotonin reuptake inhibitor : drug info - new product focus|
|© Publisher:||Medpharm Publications|
|Journal||SA Pharmaceutical Journal|
|Publication Date||Jul 2015|
|Pages||34 - 36|
|Keyword(s)||Chronicity, Major depressive disorder, Relapse, Serotonin reuptake inhibitor and Vortioxetine|
Major depressive disorder (MDD) is a disabling disease with a high risk of relapse and chronicity. Despite treatment, only 30% of patients with MDD achieve full remission. Vortioxetine is a new multimodal antidepressant. It is a serotonin reuptake inhibitor, but in addition, also has direct effects on several subtypes of serotonin receptors. It has been shown to be as effective as venlafaxine, and more effective than agomelatine in improving the symptoms of MDD. In addition, vortioxetine has been shown to improve cognitive function. It may also improve sexual dysfunction in patients who have experienced antidepressant-related sexual dysfunction with other antidepressants. Vortioxetine is generally well tolerated. The most common adverse events are mild to moderate nausea, and headaches that are usually transient in nature.
Article metrics loading...